TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvements in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate
Safety profile was favorable and consistent with previously published data
Data from the Phase 3 AGILE trial of
